Travis Vander Steen
Overview
Explore the profile of Travis Vander Steen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
87
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Steen T, Espinoza I, Duran C, Casadevall G, Serrano-Hervas E, Cuyas E, et al.
Neoplasia
. 2025 Feb;
62:101143.
PMID: 39999714
Resistance to mitochondrial apoptosis is a major driver of chemoresistance in pancreatic ductal adenocarcinoma (PDAC). However, pharmacological manipulation of the mitochondrial apoptosis threshold in PDAC cells remains an unmet therapeutic...
2.
Menendez J, Cuyas E, Encinar J, Steen T, Verdura S, Llop-Hernandez A, et al.
Mol Oncol
. 2023 Dec;
18(3):479-516.
PMID: 38158755
The initial excitement generated more than two decades ago by the discovery of drugs targeting fatty acid synthase (FASN)-catalyzed de novo lipogenesis for cancer therapy was short-lived. However, the advent...
3.
Yang L, Steen T, Espinoza I, Cuyas E, Verdura S, Menendez J, et al.
Am J Cancer Res
. 2022 Jun;
12(5):2173-2188.
PMID: 35693067
The HER3/4 ligand heregulin-β2 (HRG) is a secreted growth factor that transactivates the ligand-less receptor HER2 to promote aggressive phenotypes in breast cancer. HRG can also localize to the nucleus...
4.
Espinoza I, Kurapaty C, Park C, Steen T, Kleer C, Wiley E, et al.
Am J Cancer Res
. 2022 Mar;
12(2):839-851.
PMID: 35261806
Triple-negative/basal-like breast cancer (BC) is characterized by aggressive biological features, which allow relapse and metastatic spread to occur more frequently than in hormone receptor-positive (luminal) subtypes. The molecular complexity of...
5.
Espinoza I, Yang L, Steen T, Vellon L, Cuyas E, Verdura S, et al.
Aging (Albany NY)
. 2022 Feb;
14(3):1200-1213.
PMID: 35148282
CCN1/CYR61 promotes angiogenesis, tumor growth and chemoresistance by binding to its integrin receptor αβ in endothelial and breast cancer (BC) cells. CCN1 controls also tissue regeneration by engaging its integrin...
6.
Schroeder B, Steen T, Espinoza I, Venkatapoorna C, Hu Z, Silva F, et al.
Cell Death Dis
. 2021 Oct;
12(11):977.
PMID: 34675185
Inhibitors of the lipogenic enzyme fatty acid synthase (FASN) have attracted much attention in the last decade as potential targeted cancer therapies. However, little is known about the molecular determinants...
7.
Menendez J, Papadimitropoulou A, Steen T, Cuyas E, Oza-Gajera B, Verdura S, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33800852
The identification of clinically important molecular mechanisms driving endocrine resistance is a priority in estrogen receptor-positive (ER+) breast cancer. Although both genomic and non-genomic cross-talk between the ER and growth...
8.
Menendez J, Peirce S, Papadimitropoulou A, Cuyas E, Steen T, Verdura S, et al.
Aging (Albany NY)
. 2020 Dec;
12(24):24671-24692.
PMID: 33335078
Progesterone receptor (PR) isoforms can drive unique phenotypes in luminal breast cancer (BC). Here, we hypothesized that PR-B and PR-A isoforms differentially modify the cross-talk between prolactin and fatty acid...
9.
Papadimitropoulou A, Vellon L, Atlas E, Steen T, Cuyas E, Verdura S, et al.
Int J Mol Sci
. 2020 Oct;
21(20).
PMID: 33086721
Sustained HER2/HER3 signaling due to the overproduction of the HER3 ligand heregulin (HRG) is proposed as a key contributor to endocrine resistance in estrogen receptor-positive (ER+) breast cancer. The molecular...
10.
Menendez J, Mehmi I, Papadimitropoulou A, Steen T, Cuyas E, Verdura S, et al.
Int J Mol Sci
. 2020 Oct;
21(20).
PMID: 33081219
HER2 transactivation by the HER3 ligand heregulin (HRG) promotes an endocrine-resistant phenotype in the estrogen receptor-positive (ER+) luminal-B subtype of breast cancer. The underlying biological mechanisms that link them are,...